BIOTEST BIOTECH: Wholly-owned subsidiary Botai Zhito strategically invests in Zhejiang University Brain-Machine Interface Achievement Transformation Project

Zhitong
2025.05.22 01:24

China's first closed-loop spinal cord nerve interface implantation surgery was successfully completed recently, attracting significant attention. The surgery was jointly performed by the Second Affiliated Hospital of Zhejiang University School of Medicine and the Nanhu Brain-Machine Intersection Research Institute, among others. On the 20th, BIOTEST BIOTECH announced that it invested in Qingshi Yongjun through BoTai ZhiTou and acquired a 5% equity stake. The latter was founded by the invasive brain-machine interface team from Zhejiang University and is the first technology transfer enterprise of the Nanhu Brain-Machine Intersection Research Institute

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.